A Phase II Study of Erythropoietin for Management of Anemia Caused by Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

Next Previous
Trial Profile

A Phase II Study of Erythropoietin for Management of Anemia Caused by Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Darbepoetin alfa (Primary) ; Darbepoetin alfa (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Acronyms EPOMA

    • Most Recent Events

    • 30 Aug 2017 Planned End Date changed from 1 Dec 2017 to 31 Dec 2017.
    • 30 Aug 2017 Planned primary completion date changed from 1 Dec 2016 to 31 Dec 2017.
    • 24 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top